Last reviewed · How we verify
advanced bladder cancer
Approved treatments
Clinical guidelines
- FDA label — 1L
Indicated as a single agent for patients with transitional cell bladder cancer which is no longer amenable to local treatments, such as surgery and/or radiotherapy.
Competitive intelligence
For the full treatment-landscape CI brief — marketed leaders side-by-side, pipeline by phase, recent regulatory actions, sponsor landscape:
- advanced bladder cancer patent landscape — cliff calendar, originator estates, attackable patents
- advanced bladder cancer treatment landscape brief
- advanced bladder cancer treatment updates RSS
Frequently asked questions about advanced bladder cancer
What are the treatment guidelines for advanced bladder cancer?
FDA label publishes guidelines for advanced bladder cancer. 1 guideline references tracked.
Related
- Treatment landscape: advanced bladder cancer patent cliff · advanced bladder cancer CI report
- All diseases: Browse the disease index · Disease landscape hub
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing